References
- Burgess M, Puhalla S. BRCA1/2 mutation related and sporadic breast and ovarian cancers: more alike than different. Front Oncol 2014;4:19.
- Tewari KS, Eskander RN, Monk BJ. Development of olaparib for BCRA-deficient recurrent epithelial ovarian cancer. Clinc Cancer Res 2015;21(17):3829–3835.
- Huszno J, Budryk M, Kolosza Z, Nowara E. The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology 2013;85:278–282.
- Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 2011;130:993–1002.
- Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, et al. Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 2006;12:7033–7038.
- Armstrong DK, Bundy B, Wenzel L, et al. Intraperitonealcisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34–43.
- Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial. Lancet Oncol 2013;14:1020–1026.
- Pignata S, Scambia G, Ketsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomized, multicentre, open-label, phase 3 trial. Lancet Oncol 2014;15:396–405.
- Hereditary breast and ovarian cancer. Cancer.Net; 2015 [cited 2015 Aug 18]. Available from: http://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer
- Hillman SL, Mandrekar SJ, Bot B, DeMatteo RP, Perez EA, Ballman KV, et al. Evaluation of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol 2010;28:3002–3007.
- Mahdi H, Gockley A, Esselen K, Marquard J, Nutter B, Yang B, et al. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced state Mullerian cancer. Gynecol Oncol 2015;139(3):407–412.
- Rudaitis V, Zvirblis T, Kanopiene D, Janulynaite D, Griskevicius L, Janavicius R. BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer. Int J Gynecol Cancer 2014;24:1395–1400.
- Society of Gynecologic Oncology. SGO clinical practice statement: Genetic testing for ovarian cancer. Chicago: Society of Gynecologic Oncology; 2014 [cited 18 Aug 2015]. Available from: https://www.sgo.org/clinical-practice/guidelines/genetic-testing-for-ovarian-cancer/